Written by James Walker
Published on Vol 6 Issue 1, 2026
Well-differentiated papillary thyroid carcinoma (PTC) is generally tied to an exceptionally good outlook; nonetheless, a handful of pathological traits—most notably macroscopic extrathyroidal extension and tumor size reaching or exceeding 2 cm—have been linked with structural reappearance of disease. The present study aimed to determine which clinical and histopathological features most strongly predict disease-free survival in patients undergoing total thyroidectomy for PTC. A retrospective rev
Read More
Written by Chen Hao
Published on Vol 6 Issue 1, 2026
This investigation delivers a 5-year review, looking backward, at the provision of genetic counseling (GC) focused on hereditary cancer syndromes (HCS) within a single Bulgarian center. The intention was to map the demographic and epidemiological contours of attendees, gauge willingness to proceed to genetic testing, and catalog the array of disease-linked mutations detected. The trends point toward progressively greater engagement with GC. Prominent observations include divergent characteristic
Read More
Written by Maria Silva
Published on Vol 6 Issue 1, 2026
A notable fraction of breast cancer occurrences stems from hereditary pathogenic mutations. Germline genetic testing (GGT), especially focused on BRCA1 and BRCA2, is an indispensable component of precision oncology, enabling tailored risk classification and the formulation of individualized treatment plans. Within this report, we investigate the practicality of performing blanket testing on all freshly diagnosed breast cancer patients, without regard for age, personal or familial cancer backgrou
Read More
Written by Ali Hassan
Published on Vol 6 Issue 1, 2026
To assess how thulium laser en bloc resection of bladder tumor (ERBT) compares with conventional transurethral resection of bladder tumor (TURBT) regarding their influence on catheter-related bladder discomfort (CRBD) in individuals with bladder cancer. From January 2022 through December 2024, we retrospectively collected demographic and clinical information from patients with bladder cancer. The study included 79 patients who underwent conventional TURBT and 58 who received thulium laser ERBT.
Read More
Written by Andreas Müller
Published on Vol 6 Issue 1, 2026
Using a case-control design, this investigation explored non-genetic determinants of colorectal cancer (CRC) among individuals in South Sulawesi. The participant pool comprised 89 cases and 84 controls, spanning ages 19 to 86, with 99 men and 74 women from multiple ethnicities. Univariate assessments employed chi-square, Fisher’s exact test, t-test, and Mann-Whitney U test. A logit model with L1 regularization, adjusted for age, gender, and ethnicity, pinpointed noteworthy non-genetic risk facto
Read More
Written by Carlos Ramirez
Published on Vol 6 Issue 1, 2026
The definitive contribution of surgical cytoreduction in stage IV gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remains unclear, as corroborating data come largely from retrospective reviews that infrequently compare surgery with current systemic regimens. Drawing on a nationwide oncology registry, we compared overall survival (OS) with cytoreductive surgery versus systemic therapy alone. Eligible adults had a diagnosis of stage IV, well-differentiated GEP-NEN documented in the Nati
Read More
Written by Jinwoo Park
Published on Vol 6 Issue 1, 2026
Whether intensifying the radiotherapy dose for unresectable stage III NSCLC that is later managed with immunotherapy provides any advantage remains poorly understood. This analysis was designed to explore whether intermediate-dose escalation (IDE) yields a survival benefit in stage III NSCLC treated with definitive concurrent chemoradiation (dcCRT) and subsequent immunotherapy. The study extracted information from the National Cancer Database. All-cause mortality was evaluated through multivaria
Read More
Written by Sanjay Kulkarni
Published on Vol 6 Issue 1, 2026
Data are scarce on breast cancers (BC) identified in females with elevated genetic susceptibility, and comparisons are lacking between periods before and after they entered a sustained risk-governance scheme based on genetic risk stratification. We investigated clinical endpoints within the cohort enrolled in the Phare Grand Ouest (PGO) project. The PGO project enrolls BRCA1 and BRCA2 pathogenic variant (PV) carriers, as well as high-risk females without a BRCA PV, from eight clinical cancer gen
Read More
Written by Claire Dupont
Published on Vol 6 Issue 1, 2026
The advent of immune checkpoint inhibitors (ICIs) has fundamentally altered the treatment landscape for advanced hepatocellular carcinoma (HCC). Nevertheless, complete responses (CRs) are rarely observed, and their long-term outcomes remain incompletely delineated. This investigation explores the clinical consequences, pathologic associations, and most effective management protocols for HCC patients who achieve CR with ICI-based therapy. We performed a retrospective evaluation of 160 individuals
Read More
Written by Ahmed El-Kholy
Published on Vol 6 Issue 1, 2026
Colorectal cancer (CRC) constitutes a critical public health issue, compromising patients’ quality of life (QoL) and placing considerable strain on families and health services. To measure QoL and its associated factors among individuals with CRC in Qatar, and to determine the sociodemographic and clinical characteristics that shaped QoL during 2023. An analytical cross-sectional investigation was conducted between July and December 2023. Drawing from the National Center for Cancer Care and Rese
Read More
Written by Maria Gonzalez
Published on Vol 6 Issue 1, 2026
The goal of this work was to identify clinical indicators associated with bleeding episodes among individuals with acute leukemia receiving anticancer regimens and to develop and test a predictive nomogram based on those indicators. Encompassing 468 acute leukemia subjects, with acute promyelocytic leukemia diagnoses omitted, this retrospective cohort investigation drew on records from The Shanghai Fifth People’s Hospital and Nanyang Municipal Central Hospital covering January 2013 to December 2
Read More
Written by Bruno Martins
Published on Vol 6 Issue 1, 2026
Across the globe, cervical cancer persists as a frequent contributor to women’s deaths, with Africa bearing a disproportionate share. Nigerian statistics indicate that roughly 7093 women succumb to this illness every year. In response, the Society of Obstetrics and Gynecology of Nigeria (SOGON) formulated clinical practice guidelines to prevent cervical cancer. That said, the extent of these guidelines’ penetration into gynecological practice has not been systematically mapped. The present work
Read More
Written by Hiroshi Nakamura
Published on Vol 6 Issue 1, 2026
Surgical removal of pancreatic cancer carries a substantial risk of locoregional return of disease and peritoneal spread, contributing to a discouraging outlook. This research sought to examine the safety profile and therapeutic benefit of laparoscopic pancreaticoduodenectomy (LPD) when paired with an adapted perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) schedule for malignancies of the pancreatic head amenable to resection. This investigation employed a dual-center, retrospect
Read More
Written by Daniel Fischer
Published on Vol 6 Issue 1, 2026
Testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is carried out on pre-neoadjuvant chemotherapy (NAC) core biopsies of invasive breast carcinoma (IBC). Yet, these assays are not standard practice on post-NAC IBC specimens that harbor residual malignancy. This research contributes to understanding how shifts in ER, PR, and HER2 expression between pre- and post-NAC IBC with persistent disease correlate with prognostic endpoints, na
Read More
Written by Fatima Zahra Amrani
Published on Vol 6 Issue 1, 2026
Male breast cancer (MBC) represents an uncommonly diagnosed condition. The infrequency of its occurrence has led to a scarcity of investigations examining prognostic outcomes in this population. The present work aimed to develop a nomogram to estimate overall survival in MBC patients, followed by external validation in a Chinese patient sample. Drawing upon records within the Surveillance, Epidemiology, and End Results (SEER) database, all male subjects who first received a breast cancer diagnos
Read More
Written by Ahmed Mansour
Published on Vol 6 Issue 1, 2026
Advanced breast cancer (ABC) constitutes an incurable illness, exhibiting a median overall survival (OS) of roughly 3 years, a figure observed even within high-income settings. Survival has been prolonged by oncological therapies, particularly in hormone receptor–positive and HER2-positive disease; however, the availability of novel agents across Latin American (LATAM) nations remains constrained. An assessment of the influence of sequencing two therapeutic lines among Peruvian individuals diagn
Read More
Written by Oliver Grant
Published on Vol 6 Issue 1, 2026
Pulmonary rehabilitation is essential for maximizing recovery after lung cancer surgery, yet its clinical impact is frequently undermined by inadequate patient adherence. This investigation was designed to evaluate postoperative adherence to pulmonary rehabilitation among lung cancer patients and to identify its main determinants. A cross-sectional questionnaire-based survey was administered to individuals who had undergone lung cancer surgery, using a validated tool to gauge their rehabilitatio
Read More
Written by Claire Martin
Published on Vol 6 Issue 1, 2026
Globally, male breast cancer (MBC) is an infrequent disease presentation that carries a poorer outlook relative to its female counterpart; nonetheless, published research on MBC is sparse, particularly within resource-constrained environments. Our goal was to investigate Ki-67 expression and its links to clinicopathological parameters and intrinsic subtypes in a cohort of male breast cancer (BC) patients from a setting with limited resources. A cross-sectional methodology was utilized, drawing u
Read More
Written by Nguyen Thanh Huy
Published on Vol 6 Issue 1, 2026
Breast carcinoma constitutes the most common malignancy and ranks as the second most frequent cause of cancer-associated death among women in Canada. Approximately two-thirds of all occurrences fall under the HR+/HER2 subtype. This real-world evidence investigation was designed to deliver a thorough assessment of treatment sequences and clinical results in Canadian individuals diagnosed with early-stage HR+/HER2− breast carcinoma. This retrospective, longitudinal cohort evaluation included 541 p
Read More
Galaxy Publication is an independent scholarly publishing platform operating under the scientific and organizational designation of Eshragh Scientific and Research Center and the legal framework of ISRAK PUBLISHER EGITIM HIZMETLERI LIMITED.
The publisher is committed to ethical, transparent, and high-quality academic publishing and supports scholarly communication through internationally aligned editorial practices, publication ethics, and responsible dissemination of scientific research.
